We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Blueprint Medicines reported Sunday data from an early-stage study of BLU-667 in patients with RET-altered solid tumours, with the experimental drug showing "broad anti-tumour" activity.